---
schema_version: "secwatch.filing_event.v1"
accession: "0001935979-26-000044"
form_type: "8-K"
ticker: "BHVN"
cik: "0001935979"
company_name: "Biohaven Ltd."
filed_at: "2026-05-04T23:59:59+00:00"
generated_at: "2026-05-15T00:03:36.633388+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Biohaven Q1 net loss $130.5M; pivotal epilepsy & obesity data due 2H 2026

## Summary
- Net loss $130.5M ($0.88/sh) vs $221.7M ($2.17/sh) in Q1 2025; non-GAAP adjusted loss $102.2M ($0.69/sh).
- Cash, equivalents & securities totaled $351.8M at March 31, 2026.
- R&D spend fell to $103.8M from $187.6M, driven by program reprioritization and lower share-based compensation.
- Pivotal epilepsy (opakalim) topline readout and Phase 2 obesity (taldefgrobep) data expected in 2H 2026.
- Pivotal trials for BHV-1400 (IgAN) and BHV-1300 (Graves' disease) expected to initiate mid-2026.

## SEC filing metadata
- accession: 0001935979-26-000044
- form_type: 8-K
- ticker: BHVN
- cik: 0001935979
- company_name: Biohaven Ltd.
- filed_at: 2026-05-04T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1935979/000193597926000044/0001935979-26-000044-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1935979/000193597926000044/bhvn-20260504.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001935979-26-000044
- JSON: https://secwatch.observer/filing/0001935979-26-000044.json
- Plain text: https://secwatch.observer/filing/0001935979-26-000044.txt

## Key facts
- Earnings Releases
  Biohaven Ltd. reported financial results for first quarter ended March 31, 2026.
  - Period: first quarter ended March 31, 2026
  - Result: reported results
  source text: On May 4, 2026, Biohaven Ltd. (the " Registrant ") issued a press release announcing its financial results for the first quarter ended March 31, 2026.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1935979/000193597926000044/0001935979-26-000044-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.